Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application

A technology of obese hypertension and composition, which is applied in the field of medicine, can solve the problems of poor effect and unsatisfactory patients, blood pressure cannot be lowered, and unsatisfactory weight loss effect, etc., to achieve the protection of the structure and function of the target organ of hypertension, The effect of increasing treatment costs and reducing adverse drug reactions

Inactive Publication Date: 2016-02-24
QINGDAO YUNTIAN BIOTECH
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are a variety of treatment methods. For example, many obese patients with high blood pressure try to lose weight and lower blood pressure by taking weight-loss drugs. However, the efficacy of weight loss is very unsatisfactory, and blood pressure cannot be lowered. Poor, which ultimately leads to poor results and cannot meet the needs of patients
[0004] There are endless pharmaceutical compositions for the treatment of obese hypertension, but there is no compound that is really effective and has little side effects, and there is no combination of orlistat or selistat with Lol in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application
  • Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application
  • Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Embodiment 1: the prescription of the compound tablet of metoprolol / orlistat: (1000)

[0019]

[0020]

[0021] Preparation Process:

[0022] Weigh orlistat and metoprolol according to the prescription, use microcrystalline cellulose as filler, croscarmellose sodium and polyvinylpyrrolidone as disintegrant, and 5% PVP60% ethanol solution as binder , sodium stearate fumarate as a lubricant, one-step granulation in a fluidized bed, and then compressed into tablets.

Embodiment 2

[0023] Embodiment 2: the prescription of the compound tablet of metoprolol / orlistat: (1000)

[0024]

[0025] Preparation Process:

[0026] Weigh orlistat and metoprolol according to the prescription amount, use microcrystalline cellulose as filler, cross-linked polyvinylpyrrolidone as disintegrant, 5% PVP60% ethanol solution as binder, stearic acid fumaric acid Sodium is used as a lubricant, and it is granulated in a fluidized bed in one step, and then compressed into tablets.

Embodiment 3

[0027] Embodiment 3: the prescription of the compound tablet of metoprolol / orlistat: (1000)

[0028]

[0029] Preparation Process:

[0030] Weigh orlistat and metoprolol according to the prescription quantity, use microcrystalline cellulose as filler, croscarmellose sodium and precrosslinked starch as disintegrant, 5% PVP60% ethanol solution as adhesive agent, sodium stearate fumarate as a lubricant, one-step granulation in a fluidized bed, and then compressed into tablets, to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application and belongs to the field of medicine. The pharmaceutical composition comprises orlistat and lol-suffixed pharmaceutical active ingredients. The usage of orlistat and lol-suffixed pharmaceuticals in the pharmaceutical composition is greatly reduced, thus the risk of pharmaceuticals injuring the human body is reduced. The oral pharmaceutical composition has significant synergistic effect in treating or preventing obesity-related hypertension, can reduce the weight of a patient and the risk of hypertension being complicated by cardiovascular diseases and has higher social value.

Description

technical field [0001] The invention relates to an oral pharmaceutical composition for treating or preventing obesity-type hypertension, which belongs to the field of medicine. Background technique [0002] "Fat man" is already the term most feared by men and women, but there are indeed many fat people in real life and there is an increasing trend. Obesity has become an epidemic disease. Obesity is increasing in China and the world. A data shows that China has become the second most obese country in the world, second only to the United States. In the past 30 years, 46 million people have become "obese" and 300 million people are overweight. However, the latest data in 2015 shows that the proportion of overweight and obese people in the United States is as high as 75% and 67%, respectively. The situation in our country is also very grim. The adult overweight rate reaches 22.8%, the obesity rate reaches 7.1%, the number of overweight people reaches 200 million, and the number...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/138A61K31/536A61P9/12A61P3/04
CPCA61K31/365A61K31/138A61K31/536A61K2300/00
Inventor 王传秀
Owner QINGDAO YUNTIAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap